Argón plasma ablation versus band mucosectomy for endoscopic management of Barrett's esophagus with dysplasia or esophageal carcinoma
DOI:
https://doi.org/10.22516/25007440.432Keywords:
Barrett’s esophagus, gastroesophageal reflux, argon plasma, dysplasia in the esophagusAbstract
Introduction: Various endoscopic techniques for ablation of metaplastic esophageal epithelia which maintain the integrity of the submucosa have been described. All maintain patients under aggressive acid suppressive therapy with proton pump inhibitors. To date, few studies have compared the different endoscopic techniques for eradicating Barrett’s esophagus (BE) with dysplasia. Similarly the factors that might influence patients’ prognoses after these therapies have not been very consistently evaluated.
Objective: This is a pilot study which compares the effectiveness of complete eradication of BE with dysplasia through endoscopic mucosal resection (EMR) with bands and low voltage endoscopic argon plasma coagulation (APC). The three points evaluated are whether complete ablation of BE was achieved, the number of sessions required and whether and what complications occurred.
Methods: APC was performed using a flexible 10 French catheter. The voltage used was 50 W and flow timed varied between 1 minute and 2 l/min. In one group BE mucosa was treated with multi-band ligation. Up to six bands were placed per session. The mucosa with BE was removed with a polypectomy loop and a mixed stream of water. Patients were followed up endoscopically and biopsies were obtained from the four quadrants in both treated and untreated areas at three, six and twelve months after treatment ended. All patients received high doses of proton pump inhibitors.
Results: This prospective study describes our results in a group of 62 patients with Barrett’s Esophagus and dysplasia. Thirty-three patients (22 men, 67%) were treated with APC and 29 were treated with EMR (19 men, 66%). Complete ablation of BE was achieved in 86.2% of patients treated with EMR and in 79% of those treated with APC. The number of sessions required to achieve complete ablation was 1 ± 1 for EMR and 2 ± 1 for APC. No major complications such as gastrointestinal bleeding requiring transfusion or perforations occurred. The only complications were two cases of esophageal stenosis, one in each group. These were successfully treated with single sessions of dilation. After a mean of 68.7 ± 18.9 months of follow-up in the APC group and 50.2 ± 19.3 months in the EMR group no cases of carcinoma of the esophagus and no deaths due to disease or therapy had occurred.
Conclusions: In patients with BE with high or low grade dysplasia, APC and EMR achieve comparably high eradication rates of neoplasia and intestinal metaplasia (79% versus 86%). Both procedures have comparable levels of effectiveness and safety and have low rates of complications. Nevertheless, APC is associated with a greater number of sessions.
Downloads
References
Leeuwenburgh I, Scholten P, Calje TJ, et al. Barrett’s esophagus and esophageal adenocarcinoma are common after treatment for achalasia. Dig Dis Sci 2013; 58: 244-52.
Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119: 1149-58.
Thrift AP, Kendall BJ, Pandeya N, Whiteman DC. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013; 11: 138-44 e2.
Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013; 108: 200-7.
Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013; 11: 382-8.
Mohamed AA, Mahran KM, Zaazou MM. Impact of laparoscopic Nissen fundoplication on non-complicated Barrett’s esophagus. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 2011; 17: 185-8.
Asari R, Riegler M, Schoppmann SF. Extending Barrett’s esophagus cancer risk profile towards genetic abnormalities. Molecular cytogenetics 2013; 6: 10.
Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology 2013; 144: 62-73 e6.
Grant KS, Demeester SR, Kreger V, et al. Effect of Barrett’s esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2013.
Mulligan CR, Jr. Multidisciplinary management of esophageal cancer. Surgical oncology clinics of North America 2013; 22: 217-46.
Leggett CL, Gorospe EC, Wang KK. Endoscopic therapy for Barrett’s esophagus and early esophageal adenocarcinoma. Gastroenterology clinics of North America 2013; 42: 175-85.
Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012; 76: 1087-94.
Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc 2007; 65: 3-10.
May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14: 1085-91.
Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett’s esophagus. Gastrointest Endosc 2005; 61: 506-14.
Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc 2013; 77: 190-9.
Badreddine RJ, Prasad GA, Wang KK, et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett’s esophagus. Gastrointestinal endoscopy 2010; 71: 697-703.
Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008; 57: 1200-6.
Pouw RE, Sharma VK, Bergman JJ, Fleischer DE. Radiofrequency ablation for total Barrett’s eradication: a description of the endoscopic technique, its clinical results and future prospects. Endoscopy 2008; 40: 1033-40.
Castaño R, Rojas A. Evaluación de la eficacia de la terapia ablativa con argón plasma en el esófago de Barrett con displasia: seguimiento prospectivo no menor a un año. Rev Col Gastroenterol 2013; En prensa.
Bhat YM, Furth EE, Brensinger CM, Ginsberg GG. Endoscopic Resection with Ligation Using a Multi-Band Mucosectomy System in Barrett’s Esophagus with High-Grade Dysplasia and Intramucosal Carcinoma. Therap Adv Gastroenterol 2009; 2: 323-30.
Diaz-Cervantes E, De-la-Torre-Bravo A, Spechler SJ, et al. Banding without resection (endoscopic mucosal ligation) as a novel approach for the ablation of short-segment Barrett’s epithelium: results of a pilot study. The American journal of gastroenterology 2007; 102: 1640-5.
Fleischer DE, Wang GQ, Dawsey S, et al. Tissue band ligation followed by snare resection (band and snare): a new technique for tissue acquisition in the esophagus. Gastrointest Endosc 1996; 44: 68-72.
Tomizawa Y, Iyer PG, Wong Kee Song LM, Buttar NS, Lutzke LS, Wang KK. Safety of endoscopic mucosal resection for Barrett’s esophagus. Am J Gastroenterol 2013; 108: 1440-7; quiz 8.
May A, Gossner L, Behrens A, et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc 2003; 58: 167-75.
Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002; 51: 130-1.
Coupland VH, Lagergren J, Luchtenborg M, et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008. Gut 2013; 62: 961-6.
Mork H, Barth T, Kreipe HH, et al. Reconstitution of squamous epithelium in Barrett’s oesophagus with endoscopic argon plasma coagulation: a prospective study. Scand J Gastroenterol 1998; 33: 1130-4.
Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett’s esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810-5.
Manner H, May A, Faerber M, Rabenstein T, Ell C. Safety and efficacy of a new high power argon plasma coagulation system (hp-APC) in lesions of the upper gastrointestinal tract. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2006; 38: 471-8.
Vargo JJ. Clinical applications of the argon plasma coagulator. Gastrointest Endosc 2004; 59: 81-8.
Inoue H, Takeshita K, Hori H, Muraoka Y, Yoneshima H, Endo M. Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 1993; 39: 58-62.
Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial. Gut 2004; 53: 785-90.
Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I. Endoscopic ablation of dysplastic Barrett’s oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 2005; 40: 750-8.
Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Endoscopic ablation of Barrett’s oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004; 20: 1289-96.
Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Ablation treatment for Barrett oesophagus: what depth of tissue destruction is needed? Journal of clinical pathology 1999; 52: 509-12.
Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348: 584-5.
Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus. Gut 2000; 46: 574-7.
Bonavina L, Ceriani C, Carazzone A, Segalin A, Ferrero S, Peracchia A. Endoscopic laser ablation of nondysplastic Barrett’s epithelium: is it worthwhile? Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 1999; 3: 194-9.
Shand A, Dallal H, Palmer K, Ghosh S, MacIntyre M. Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut 2001; 48: 580-1.
Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology 2013; 145: 79-86 e1.
Fernandez-Sordo JO, Konda VJ, Chennat J, et al. Is Endoscopic Ultrasound (EUS) necessary in the pre-therapeutic assessment of Barrett’s esophagus with early neoplasia? Journal of gastrointestinal oncology 2012; 3: 314-21.
Bulsiewicz WJ, Dellon ES, Rogers AJ, et al. The impact of endoscopic ultrasound findings on clinical decision making in Barrett’s esophagus with high-grade dysplasia or early esophageal adenocarcinoma. Dis Esophagus 2012.
Van Laethem JL, Cremer M, Peny MO, Delhaye M, Deviere J. Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-51.
Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett’s esophagus. Am J Gastroenterol 2000; 95: 1661-8.
Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett’s epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000; 51: 659-63.
Tigges H, Fuchs KH, Maroske J, et al. Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett’s esophagus. J Gastrointest Surg 2001; 5: 251-9.
Morris CD, Byrne JP, Armstrong GR, Attwood SE. Prevention of the neoplastic progression of Barrett’s oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001; 88: 1357-62.
Basu KK, Pick B, Bale R, West KP, de Caestecker JS. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium. Gut 2002; 51: 776-80.
Kahaleh M, Van Laethem JL, Nagy N, Cremer M, Deviere J. Long-term follow-up and factors predictive of recurrence in Barrett’s esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002;34:950-5.
Garewal H, Ramsey L, Sharma P, Kraus K, Sampliner R, Fass R. Biomarker studies in reversed Barrett’s esophagus. Am J Gastroenterol 1999; 94: 2829-33.
Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett’s esophagus after photodynamic therapy. Gastroenterology 2000; 119: 624-30.
van Hillegersberg R, Haringsma J, ten Kate FJ, Tytgat GN, van Lanschot JJ. Invasive carcinoma after endoscopic ablative therapy for high-grade dysplasia in Barrett’s oesophagus. Digestive surgery 2003; 20: 440-4.
Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett’s epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy 2014; 46: 6-12.
Pouw RE, Bergman JJ. Argon plasma coagulation for Barrett’s neoplasia: the right hot ingredient for a successful recipe? Endoscopy 2014; 46: 13-5.
Sie C, Bright T, Schoeman M, et al. Argon plasma coagulation ablation versus endoscopic surveillance of Barrett’s esophagus: late outcomes from two randomized trials. Endoscopy 2013.
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
